Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers

NCT01846520 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2020-01-23

No results posted yet for this study

Summary

This randomized clinical trial studies the Family Caregiver Palliative Care Intervention in supporting caregivers of patients with stage II-IV gastrointestinal, gynecologic, urologic and lung cancers. Education and telephone counseling may reduce stress and improve the well-being and quality of life of caregivers of cancer patients.

Conditions

  • Healthy Subject
  • Localized Transitional Cell Cancer of the Renal Pelvis and Ureter
  • Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter
  • Psychosocial Effects of Cancer and Its Treatment
  • Recurrent Bladder Cancer
  • Recurrent Cervical Cancer
  • Recurrent Colon Cancer
  • Recurrent Gastric Cancer
  • Recurrent Ovarian Epithelial Cancer
  • Recurrent Ovarian Germ Cell Tumor
  • Recurrent Pancreatic Cancer
  • Recurrent Rectal Cancer
  • Recurrent Renal Cell Cancer
  • Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter
  • Recurrent Urethral Cancer
  • Recurrent Uterine Sarcoma
  • Regional Transitional Cell Cancer of the Renal Pelvis and Ureter
  • Stage II Bladder Cancer
  • Stage II Renal Cell Cancer
  • Stage II Urethral Cancer
  • Stage IIA Cervical Cancer
  • Stage IIA Colon Cancer
  • Stage IIA Gastric Cancer
  • Stage IIA Ovarian Epithelial Cancer
  • Stage IIA Ovarian Germ Cell Tumor
  • Stage IIA Pancreatic Cancer
  • Stage IIA Rectal Cancer
  • Stage IIA Uterine Sarcoma
  • Stage IIB Cervical Cancer
  • Stage IIB Colon Cancer
  • Stage IIB Gastric Cancer
  • Stage IIB Ovarian Epithelial Cancer
  • Stage IIB Ovarian Germ Cell Tumor
  • Stage IIB Pancreatic Cancer
  • Stage IIB Rectal Cancer
  • Stage IIB Uterine Sarcoma
  • Stage IIC Colon Cancer
  • Stage IIC Ovarian Epithelial Cancer
  • Stage IIC Ovarian Germ Cell Tumor
  • Stage IIC Rectal Cancer
  • Stage III Bladder Cancer
  • Stage III Pancreatic Cancer
  • Stage III Renal Cell Cancer
  • Stage III Urethral Cancer
  • Stage IIIA Cervical Cancer
  • Stage IIIA Colon Cancer
  • Stage IIIA Gastric Cancer
  • Stage IIIA Ovarian Epithelial Cancer
  • Stage IIIA Ovarian Germ Cell Tumor
  • Stage IIIA Rectal Cancer
  • Stage IIIA Uterine Sarcoma
  • Stage IIIB Cervical Cancer
  • Stage IIIB Colon Cancer
  • Stage IIIB Gastric Cancer
  • Stage IIIB Ovarian Epithelial Cancer
  • Stage IIIB Ovarian Germ Cell Tumor
  • Stage IIIB Rectal Cancer
  • Stage IIIB Uterine Sarcoma
  • Stage IIIC Colon Cancer
  • Stage IIIC Gastric Cancer
  • Stage IIIC Ovarian Epithelial Cancer
  • Stage IIIC Ovarian Germ Cell Tumor
  • Stage IIIC Rectal Cancer
  • Stage IIIC Uterine Sarcoma
  • Stage IV Bladder Cancer
  • Stage IV Gastric Cancer
  • Stage IV Ovarian Epithelial Cancer
  • Stage IV Ovarian Germ Cell Tumor
  • Stage IV Pancreatic Cancer
  • Stage IV Renal Cell Cancer
  • Stage IV Urethral Cancer
  • Stage IVA Cervical Cancer
  • Stage IVA Colon Cancer
  • Stage IVA Rectal Cancer
  • Stage IVA Uterine Sarcoma
  • Stage IVB Cervical Cancer
  • Stage IVB Colon Cancer
  • Stage IVB Rectal Cancer
  • Stage IVB Uterine Sarcoma
  • Ureter Cancer
  • Stage IIA Lung Carcinoma
  • Stage IIB Lung Carcinoma
  • Stage IIIA Lung Carcinoma
  • Stage IIIB Lung Carcinoma

Interventions

OTHER

educational intervention

Receive FCPCI home education sessions

BEHAVIORAL

telephone-based intervention

Receive FCPCI telephone support sessions and 24 hour telephone support

PROCEDURE

quality-of-life assessment

Ancillary studies

OTHER

questionnaire administration

Ancillary studies

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH
  • American Cancer Society (ACS) National Office

    collaborator UNKNOWN
  • City of Hope Medical Center

    lead OTHER

Principal Investigators

  • Betty Ferrell · City of Hope Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2019-05-23
Completion
2019-05-23

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01846520 on ClinicalTrials.gov